Loading stock data…
PCSA
$2.04-0.39 (-15.91%)
After Hours$2.12+0.08 (+4.18%)· Last close Jun 9
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Processa Pharmaceuticals, Inc. in the Healthcare sector is trading at $2.04. The stock is currently near its 52-week low of $1.76, remaining 53.8% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$2.04
Potential Downside
0%
Whystock Fair Value$2.04
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved onco...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-555.19%
Volume
Today's trading volume
108,543
Recent News
Wall Street Set to Open Higher Thursday as Inflation Rises Less Than Expected; Jobless Claims Decline
US stocks look set to open higher in Thursday's trading session as investors dissect key inflation a
Top Midday Gainers
Processa Pharmaceuticals (PCSA) said Wednesday that an update from its phase 2 study of a combinatio
Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Insider Stock Buyers At Processa Pharmaceuticals Recouped Some Losses This Week
Insiders who bought US$213.4k worth of Processa Pharmaceuticals, Inc. ( NASDAQ:PCSA ) stock in the last year recovered...
Processa Pharmaceuticals, Inc. (PCSA) Secures Buy Rating on Portfolio Progress
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) is among the fundamentally strong penny stocks to invest in. Analysts at H.C. Wainwright have reiterated their Buy rating on Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) while maintaining a price target of $2, implying an upside of over 900%. This overwhelming optimism stems from the company’s comprehensive portfolio update just a few days […]